TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8636588

Group type: EXPERIMENTAL
Intervention: Intervention group (computer-generated drug list to cancel or renew RXs)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (could not cancel outpatient drugs, wrote all medications on individual prescriptions)
Number of subjects: 348
Study: 1390495

Group type: EXPERIMENTAL
Intervention: Cyclosporin A 5 mg/kg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cyclophosphamide 1 g intravenous boluses monthly
Number of subjects: 23
Study: 3893815

Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg b.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg b.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29044521

Group type: EXPERIMENTAL
Intervention: Tongue scraper (TS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Toothbrush (TB)
Number of subjects: 18
Study: 27682493

Group type: EXPERIMENTAL
Intervention: Compound monoammonium glycyrrhizinate combined with dandelion (TCM group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 80
Study: 24666618

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 7595

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 7595

Group type: EXPERIMENTAL
Intervention: Change in body weight
Number of subjects: 7595

Group type: EXPERIMENTAL
Intervention: Change in body weight in patients with NODM
Number of subjects: 7595

Group type: EXPERIMENTAL
Intervention: Change in body weight and NODM risk
Number of subjects: 7595
Study: 22659151

Group type: EXPERIMENTAL
Intervention: High-speed power training for 12 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Detraining (DT) for 6 weeks after training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 37
Study: 21038754

Group type: EXPERIMENTAL
Intervention: CO2 laser (continuous wave mode, 5 W)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CO2 laser (pulsed char-free mode)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diode laser (5.12 W, pulsed mode)
Number of subjects: 15
Study: 18625920

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) behaviors
Number of subjects: 287

Group type: COMPARATOR
Intervention: Older physicians
Number of subjects: 287

Group type: COMPARATOR
Intervention: Physicians in health maintenance organization settings
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Longer visit duration
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: SPs making general medication requests
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: SPs making brand-specific medication requests
Number of subjects: 287
Study: 16273800

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified versions of the FIQ (1997 and 2002)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Translated versions of the FIQ
Number of subjects: 0
Study: 11822921

Group type: EXPERIMENTAL
Intervention: 2 mL of hyaluronate sodium at a concentration of 10 mg/mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti‐inflammatory drugs (NSAIDs) (75 mg of diclofenac and 200 microg of misoprostol) and hyaluronate sodium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NSAIDs and placebo (2 mL of isotonic sodium chloride solution [saline])
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (lactose and saline)
Number of subjects: 120
Study: 9894580

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 0
Study: 8619109

Group type: EXPERIMENTAL
Intervention: Pre-operative internal brachytherapy (two alternative doses)
Number of subjects: 0
Study: 2203305

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g daily for 14 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 36
Study: 7212794

Group type: EXPERIMENTAL
Intervention: Whole blood (WB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Packed red blood cells (PRBC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (WB and PRBC)
Number of subjects: 28
Study: 31995811

Group type: EXPERIMENTAL
Intervention: Nicotine and varenicline administration during abstinence
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Varenicline administration
Number of subjects: 44
Study: 30839408

Group type: EXPERIMENTAL
Intervention: GALILEI Scheimpflug camera
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of GALILEI and Pentacam
Number of subjects: 50
Study: 28960283

Group type: EXPERIMENTAL
Intervention: Experimental videos (role competency and social inclusion)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Experimental videos and control
Number of subjects: 295
Study: 28459236

Group type: EXPERIMENTAL
Intervention: 6 g/day sugarcane bagasse plus conventional treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo plus conventional treatment
Number of subjects: 196
Study: 24481688

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (220 μg folic acid, 1.1 mg vitamin B2, 0.73 mg B6, 1.2 μg B12, 130 mg calcium)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Calcium only (control group)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation
Number of subjects: 250

Group type: COMPARATOR
Intervention: B vitamin supplementation and Calcium only (control)
Number of subjects: 250
Study: 21272705

Group type: EXPERIMENTAL
Intervention: 10% protein condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15% protein condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20% protein condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 25% protein condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30% protein condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: All protein conditions (10% to 30%)
Number of subjects: 18
Study: 19953989

Group type: EXPERIMENTAL
Intervention: RHEOSORBILACTUM
Number of subjects: 60

Group type: COMPARATOR
Intervention: VENOFUNDIN
Number of subjects: 60
Study: 16769942

Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study: 15284736

Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 2 x 1 pocket technique
Number of subjects: 1000
Study: 11688901

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Josamycin
Number of subjects: 156
Study: 9206631

Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 74
Study: 7697694

Group type: EXPERIMENTAL
Intervention: 1 mg loperamide oxide
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 2 mg loperamide oxide
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg loperamide oxide
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Loperamide oxide
Number of subjects: 230
Study: 3308343

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 90
Study: 31898006

Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: Xience EES
Number of subjects: 2152
Study: 29476810

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal ovarian needle drilling (TND)
Number of subjects: 246
Study: 27931564

Group type: EXPERIMENTAL
Intervention: New systematic communication approach between medical staff and patients' relatives
Number of subjects: 291

Group type: COMPARATOR
Intervention: Pre-intervention period (2007-2012)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Post-intervention period (2013-2015)
Number of subjects: 291
Study: 24742970

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined aliskiren (150 mg/day) and losartan (100 mg/day)
Number of subjects: 155
Study: 23806094

Group type: EXPERIMENTAL
Intervention: Tailored intervention (personalized skin cancer education through the mail)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (generic skin cancer information materials)
Number of subjects: 0
Study: 21679006

Group type: EXPERIMENTAL
Intervention: Estradiol valerate/dienogest
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ethinylestradiol/levonorgestrel
Number of subjects: 29
Study: 19049700

Group type: EXPERIMENTAL
Intervention: GOP‐A‐Flu (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tamiflu (reference)
Number of subjects: 24
Study: 16818983

Group type: EXPERIMENTAL
Intervention: Static plate construct
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dynamic plate constructs
Number of subjects: 21

Group type: COMPARATOR
Intervention: All tested anterior cervical plating systems
Number of subjects: 21
Study: 12699022

Group type: EXPERIMENTAL
Intervention: Preventive intervention group
Number of subjects: 158

Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 158
Study: 10886592

Group type: EXPERIMENTAL
Intervention: R‐568 (100 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8933119

Group type: COMPARATOR
Intervention: Bulgofilus (fermented milk enriched with Lactobacillus bulgaricus)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ofilus (fermented milk containing Lactobacillus acidophilus and Bifidobacterium sp.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional yoghurt
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactulose (control)
Number of subjects: 14
Study: 1559738

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg twice daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cefadroxil 500 mg twice daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 164
Study: 3902362

Group type: EXPERIMENTAL
Intervention: PGE2 (0.5 mg) administered every 4 h via nasogastric tube
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administered every 4 h via nasogastric tube
Number of subjects: 90
Study: 31432072

Group type: EXPERIMENTAL
Intervention: Low-glycemic whole-grain dietary pattern (WG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dietary pattern high in refined grains and added sugars (RG)
Number of subjects: 80
Study: 30043079

Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study: 26111826

Group type: EXPERIMENTAL
Intervention: Continuous-fingolimod 0.5 mg
Number of subjects: 1027

Group type: COMPARATOR
Intervention: IFN-switch (switched from interferon β‐1a to fingolimod)
Number of subjects: 1027
Study: 24588989

Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diagnostic laparoscopy (Control)
Number of subjects: 50
Study: 22910291

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 treatment for 1 year
Number of subjects: 21
Study: 21047591

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer with a 6 year interval
Number of subjects: 50
Study: 17969401

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (doxorubicin+paclitaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy with aromatase inhibitors (anastrazole or exemestane)
Number of subjects: 0
Study: 15454357

Group type: EXPERIMENTAL
Intervention: Oncologist exercise recommendation only
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Oncologist exercise recommendation plus referral to an exercise specialist
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Recall of exercise recommendation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study: 11793169

Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg/day, daily; n = 23)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Etidronate (200 mg/day, 14 days per 3 months; n = 25)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium lactate (2 g/day, daily; n = 24)
Number of subjects: 72
Study: 9672958

Group type: EXPERIMENTAL
Intervention: Training plus ongoing consultation and networking for clinic team leaders (I)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care without additional training (C)
Number of subjects: 44
Study: 8005130

Group type: EXPERIMENTAL
Intervention: verapamil 360 mg.day-1
Number of subjects: 1757

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1757
Study: 2679444

Group type: EXPERIMENTAL
Intervention: Gestrinone (2 x 2.5 mg/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Danazol (3 x 200 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day intranasally)
Number of subjects: 30
Study: 59517

Group type: EXPERIMENTAL
Intervention: Bishydroxycoumarin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 54

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Phenindione
Number of subjects: 54
Study: 30696504

Group type: EXPERIMENTAL
Intervention: Overfeeding by 50% (16,132 (sd 889) kJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Energy balance trial (10,755 (sd 593) kJ)
Number of subjects: 12
Study: 27647279

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 26015443

Group type: EXPERIMENTAL
Intervention: PRP-augmented repair
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional repair
Number of subjects: 74
Study: 23647007

Group type: EXPERIMENTAL
Intervention: Tx 1: xenogenic bone substitute (pre‐hydrated collagenated cortico‐cancellous porcine bone) and free gingival graft
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tx 2: free gingival graft alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tx 4: no further treatment (control)
Number of subjects: 30
Study: 21727288

Group type: EXPERIMENTAL
Intervention: Relaxation massage
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Structural massage
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 401
Study: 19860888

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000/5 gel
Number of subjects: 9404

Group type: EXPERIMENTAL
Intervention: 2% PRO 2000/5 gel
Number of subjects: 9404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9404
Study: 16340516

Group type: EXPERIMENTAL
Intervention: Quit & Win
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: NRT voucher
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 1849

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1849
Study: 16032448

Group type: EXPERIMENTAL
Intervention: PCEA (Patient-controlled epidural analgesia)
Number of subjects: 58

Group type: COMPARATOR
Intervention: CEI (Conventional continuous epidural infusion)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 58

Group type: COMPARATOR
Intervention: CEI
Number of subjects: 58
Study: 12399689

Group type: EXPERIMENTAL
Intervention: Daily supervised brushing with 1,500-ppm fluoride toothpaste and rinsing with a beaker of water (School A)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Daily supervised brushing with 1,500-ppm fluoride toothpaste and only permitted to spit out once after brushing (School B)
Number of subjects: 407

Group type: COMPARATOR
Intervention: No daily brushing and no supply of toothpaste (School C)
Number of subjects: 407
Study: 10833286

Group type: EXPERIMENTAL
Intervention: Coronally Positioned Flap (CPF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental Technique (ET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical Debridement (Control)
Number of subjects: 60
Study: 7478782

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilator (IPV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard aerosol and chest physiotherapy
Number of subjects: 16
Study: 2179590

Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12866
Study: 347461

Group type: EXPERIMENTAL
Intervention: Experimental mouthwash containing cetyl pyridinium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial mouthwash (Scope)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial mouthwash (Listerine)
Number of subjects: 0
Study: 31867987

Group type: EXPERIMENTAL
Intervention: Training in Remaking Recess only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training in Remaking Recess with implementation support
Number of subjects: 28
Study: 31146440

Group type: EXPERIMENTAL
Intervention: Higher-protein breakfast (HP; 350 kcal; 35 g protein)
Number of subjects: 37
Study: 28103811

Group type: EXPERIMENTAL
Intervention: Interactive modular tiles training (2 sessions per week for 12 weeks, 1 hour per session with 13 minutes of training per participant)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care provided to non-patient elderly
Number of subjects: 60
Study: 25983216

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Ranibizumab combined with laser
Number of subjects: 396

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 396
Study: 23495860

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol
Number of subjects: 2734
Study: 21195605

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control (routine medical care)
Number of subjects: 418
Study: 19190496

Group type: EXPERIMENTAL
Intervention: 18-month lamivudine monotherapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 154
Study: 17259157

Group type: EXPERIMENTAL
Intervention: Estrogen (3 mg estrostilben thrice a day from the day before acrinol injection to the end of delivery)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no estrogen treatment)
Number of subjects: 320
Study: 15135192

Group type: EXPERIMENTAL
Intervention: Over-the-head CPR (OTH CPR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study: 11501645

Group type: EXPERIMENTAL
Intervention: Cream A (high lipid content)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cream B (moderate/low lipid content)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no moisturizer)
Number of subjects: 19
Study: 9932659

Group type: EXPERIMENTAL
Intervention: Accutrend Sensor (Boehringer Mannheim GmbH)
Number of subjects: 20
Study: 8057114

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 200 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study: 3141194

Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen/day and 150 mg testolactone/day
Number of subjects: 40
Study: 4530838

Group type: EXPERIMENTAL
Intervention: Unconventional toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard toothbrush
Number of subjects: 0
Study: 31296508

Group type: EXPERIMENTAL
Intervention: Mindfulness-based joyful sleep
Number of subjects: 70

Group type: COMPARATOR
Intervention: CBT-I
Number of subjects: 70
Study: 28993867

Group type: EXPERIMENTAL
Intervention: Selective pelvic arterial embolisation (PAE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no PAE)
Number of subjects: 38
Study: 25186850

Group type: EXPERIMENTAL
Intervention: Student Examiners (SE)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Faculty Examiners (FE)
Number of subjects: 207
Study: 24009792

Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) aiming for coverage of children between 80%-90%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) aiming for coverage > 90%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) for three years
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rule of cessation of MDA early if estimated prevalence of ocular C. trachomatis infection was less than 5%
Number of subjects: 32
Study: 21315216

Group type: EXPERIMENTAL
Intervention: CCM plus optimal medical therapy (OMT)
Number of subjects: 428

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: CCM plus OMT
Number of subjects: 428
Study: 18990434

Group type: COMPARATOR
Intervention: 75 mg aspirin with 150 mg clopidogrel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 160 mg aspirin with 150 mg clopidogrel
Number of subjects: 50
Study: 16874595

Group type: EXPERIMENTAL
Intervention: Combined dietary-physical activity intervention
Number of subjects: 24
Study: 15526839

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (200 IU, thrice a week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium carbonate (up to 6 g/d) alone or with aluminum hydroxide (up to 3 g/d) as phosphate binders
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 45
Study: 11288783

Group type: EXPERIMENTAL
Intervention: Bioactive glass (PG) bone replacement graft material
Number of subjects: 27

Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (ePTFE) barrier membrane
Number of subjects: 27